Table 4.
Univariate and Multivariate Analysis of the Prognostic Factors for PFS in All Patients
| Varaible | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender(Male vs Female) | 1.11(0.52–2.37) | 0.792 | ||
| Age(≥65 vs <65 years) | 0.57(0.3–1.1) | 0.045 | 0.66 (0.41 −0.93) | 0.03 |
| ECOG-PS(0 vs 1) | 0.92(0.48–1.77) | 0.813 | ||
| BCLC stage(B vs C) | 0.93(0.53–1.63) | 0.802 | ||
| Child pugh(A vs B) | 0.67(0.31–1.42) | 0.293 | ||
| AFP(≥400 vs <400g/mL) | 0.62(0.34–1.12) | 0.116 | ||
| HBV(Present vs Absent) | 0.95(0.49–1.87) | 0.892 | ||
| Tumorsize | 1(0.94–1.08) | 0.931 | ||
| Tumorsize(≥10 vs <10cm) | 0.98(0.54–1.76) | 0.934 | ||
| Tumor number(Single vs Multiple) | 1.17(0.66–2.06) | 0.597 | ||
| Macrovascular invasion(Yes vs No) | 0.73(0.42–1.28) | 0.275 | ||
| ALBI stage | 1.01(0.64–1.58) | 0.972 | ||
| ALT(<40 vs ≥40U/L) | 0.74(0.41–1.35) | 0.325 | ||
| AST(<40 vs ≥40U/L) | 0.89(0.51–1.57) | 0.694 | ||
| TBil(<17 vs ≥17μmol/L) | 1.32(0.7–2.47) | 0.393 | ||
| Treatment | 0.55(0.31–0.98) | 0.044 | 0.55(0.31–0.98) | 0.0439 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; ALBI, albumin-bilirubin; AFP, ɑ-fetoprotein; HBV, Hepatitis B virus; TBil, total bilirubin.